ArticlePakistan journal of medical sciences2025
Efficacy of Pyrotinib combined with Trastuzumab in the treatment of patients with human epidermal growth factor receptor-2 positive breast cancer.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trastuzumab Deruxtecan as a Salvage Therapy after Disitamab Vedotin Failure in HER2 Altered Solid Tumors: A Preliminary Real-world Comparative Study.Pakistan journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the efficacy of Pyrotinib combined with Trastuzumab in the treatment of human epidermal growth factor-2 (HER-2) positive breast cancer (BC). Methods: This was a retrospective study that enrolled 150 patients with HER-2 positive BC admitted to Hengyang Medical School, University of South China from January 2021 to October 2023. Among them, 73 patients were treated with Trastuzumab alone (Trastuzumab group), and 77 cases were treated with combined Pyrotinib and Trastuzumab (combined group). Tumor response, tumor marker levels, immune function, and incidence of toxic side effects were compared between the two groups. Results: Tumor response of the combined group (94.81%) was significantly higher than that of the Trastuzumab group (84.93%) ( Conclusions: Compared with Trastuzumab alone, a combined regimen of Pyrrolitinib and Trastuzumab is equally safe, and improving immune function, reducing the level of tumor markers, and improving tumor response in patients with HER-2 positive BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.